- LOGIN
- MemberShip
- 2025-12-18 10:04:48
- Product
- Disaster subsidies must be paid to all citizens
- by Jung, Heung-Jun Apr 09, 2020 06:26am
- 9 out of 10 Dailypharm readers expressed their opinion that the government's emergency disaster aid under COVID-19 should be paid to the entire population, not just the bottom 70% of income. Dailypharm conducted an opinion poll on how to pay for emergency disaster aid through the online survey of Issue & Poll from the 1st to the 7th. Of the 262 Daily Farm readers working in the health and medical industry, 87.8% (230 people) said that all citizens should receive disaster relief funds. Only 12.2% (32 people) voted in favor of the government method of paying the bottom 70%. The readers in favor of the payment of the whole nation thought that it would be reasonable to give it to the whole nation even if the amount was lowered a little. On the other hand, those who favored the selective payment method for the lower 70% insisted that it would be better to pay only the lower 30% or even a little more to the lower income class.
- Product
- Boots, withdraws from the pharmacy market in 3 years
- by Kim JiEun Apr 08, 2020 06:21am
- 'Boots', which opened ambitiously in Korea, claiming to be a premium health & beauty store, eventually withdrew their business after failing to overcome the continuing sluggish profitability. According to the industry on the 6th, the company recently decided to withdraw its entire business and closed the recently opened stores. In 2017, E-Mart received a lot of attention in the H&B market as it landed in Korea by exclusively contracting with Walgreen Boots Alliance, the UK's No.1 H & B store company. In addition to opening and operating 33 stores only in the year of landing in Korea, it was also differentiated from existing H & B stores based on “Premium”. However, it was reported that e-mart decided to withdraw its business after failing to overcome the continued deficit and deteriorating profitability. It is also analyzed that the boots that failed to dominate the competition with other H & B stores in Korea are factors that failed. E-Mart closed 18 boots stores in the first half of last year, and it was confirmed that the six remaining stores were closed in turn following the closing of Starfield COEX and Sinchon stores earlier this year. With the withdrawal of the boots business, the pharmacies operated by each store were forced to close. It is known that there are about 6 pharmacies in Boots, 4 of which are now closed, and the other 2 are in business and are in negotiations with the head office. Boots Star Pharmacy in Starfield Hanam branch also closed on the 5th. At the time of opening the store, it contracted for a 5-year lease, but the business was withdrawn after 3 years of opening, so the branch could not fill the contract period and stopped operating the pharmacy. Yong-han Choi, Rph, said the branch had planned to withdraw from business since February, and that road shops were almost closed. Stores and pharmacies were closed on the 5th, when the discount event to remove inventories ended. Pharmacist Choi said it was unfortunate that the branch was the first pharmacy and could not finish the five-year contract period, and in fact it was closed by a compromise. He added that he plans to rent another store in Starfield Hanam, where he opened the pharmacy independently, and it is just like starting a new one.
- Product
- President Moon posted a memorial message on SNS
- by Kang, Shin-Kook Apr 07, 2020 06:40am
- On the 4th, President Moon Jae-in expressed his condolences to Ms. A, a medical doctor working in Gyeongsan, Gyeongbuk, infected with COVID-19. President Moon said through social networking services (SNS), "It was very sad that our infected medical staff was sacrificed for the first time while treating a COVID-19 infected patient." Mr. A, who ran a private clinicl, died while undergoing treatment after being diagnosed with COVID-19, showing symptoms of pneumonia after treating a COVID-19 confirmed patient in February. President Moon said he wishes the tranquil rest of the deceased, who was always strict to himself and kind to the patient, and said that the people will be of the same mind and give deep comfort to his family. In addition, President Moon welcomed the spring of April, saying that he would not be able to tell the sadness of the MD’s family who could not keep his self-isolated state even at the moment of leaving, but he sincerely pay tribute to the medical staff who don't take care of their bodies to overcome the unfinished COVID-19 disease. President Moon emphasized that aside from his clinic work, the enthusiasm to run for medical care is helping the community overcome COVID-19. and The medical staff is enough to win everyone's respect. " On the other hand, the KMA also held a time of silence for 1 minute at noon on the 4th to commemorate the deceased MD A.
- Product
- Does Tylenol prevent COVID-19 infection?
- by Kim JiEun Apr 03, 2020 06:34am
- Tylenol stockpiles are showing signs of prolongation which were initiated by the World Health Organization (WHO) According to pharmacies on the 1st, there are more customers who want to buy Tylenol, and many of them want to buy in bulk. Tylenol's full-scale hoarding began after WHO recently advised patients with suspicion of COVID-19 to use antipyretic analgesic “Acetaminophen” instead of anti-inflammatory analgesic “Ibuprofen”. Two days after the recommendation, the WHO withdrew its content on the grounds of lack of grounds. but pharmacists say that the purchase of nominations for acetaminophen-based tylenol is increasing. Since the first occurrence of COVID-19 confirmed patients, purchases of ready-to-use medicines increased and Tylenol stockpiling overlapped, making it difficult for pharmacists to secure inventory immediately. Currently, most of the Tylenol products are sold out in the online shopping malls used by pharmacists, and it is not easy to order separately through wholesalers. The number of patients seeking Tylenol suddenly increased, and a pharmacist in Seoul confirmed that there was a WHO recommendation. The pharmacist also said that some patients bought a lot of Tylenol at a time and took it regularly every day, even turning to fake news that Tyrenol has a COVID-19 preventive effect. A local pharmacist said, “Since the spread of COVID-19, there have been some shortage of OTC medications, as well as Tylenol. Tylenol has become more intense in recent years. Some hospitals even recommend or take prescriptions as a preventive measure. Pharmacists are concerned that such an overdose of acetaminophen-based tylenol may cause side effects such as gastrointestinal disorders. In addition, the hypothesis that some of the Acetaminophen that are currently being raised alleviate or prevent the early symptoms of COVID-19, an infectious disease, is an unconfirmed part and warns that it can be dangerous if patients believe it Another pharmacist in Seoul said that Acetaminophen may cause side effects such as gastrointestinal disorders when taken in excess, and may conceal fever when taken for a long time, so it is more likely to cause disease if patients do social activities for a long time while it is hidden. Reflecting this situation, the Ministry of Health and Welfare also advised frontline pharmacies to provide adequate medication guidance regarding the sale of antipyretics. The government recommends that people who have fever or respiratory symptoms (cough, sore throat, muscle pain, etc.) do not go to work and get enough rest through a strong social distance. When selling antipyretic drugs such as acetaminophen and ibuprofen, the government hopes to cooperate so that sufficient medication guidance such as efficacy, effectiveness, and precautions for use can be achieved.
- Product
- 7 out of 10 doctors, the government was wrong with COVID-19
- by Kang, Shin-Kook Apr 01, 2020 06:17am
- Seven out of ten doctors found that the government's response to the COVID-19 was wrong. The Korean Medical Association (Chairman Dae-Zip Choi) conducted a questionnaire survey on the COVID-19 events through the doctoral survey on the 20th to 24th, and published the results on the 30th. As a result of the survey, 39.1% (621 people) of the respondents answered that 'correct responses were not achieved at all' and 29.8% (473 people) answered that 'correspondence was somewhat insufficient' It was found that 68.9% of all respondents in the year were negatively evaluated. On the other hand, 16.6% (264 people) said that 'it worked to some extent' and 6.1% (97 people) said that they responded very well. In particular, the negative evaluation of doctors in the Daegu area, which suffered the most, was 83.2%, which is the only city in the country that has surpassed 80%. Regarding the 'restriction on the total entry of people via China', 84.1% (1337 people) of respondents said that 'there was a need to restrict the entry of people via China at the beginning of the situation'. Following this, 12.6% (200 people) said that 'there was no need to expand the limit of immigration via China' and 3.3% (52 people) said 'I don't know', and there were overwhelmingly negative opinions on the government response in the early stages of the situation. As for the KMA's response to the COVID-19 incident, the percentage of respondents who answered 'comparably appropriately responded' and 'very appropriately responded' was 44.6% (706 people) and 17.9% (284 people), respectively, accounting for 62.5% (990) People) as appropriate. On the other hand, 14.0% (221 people) had an opinion that 'the response was somewhat insufficient', and 7.6% (120 people) had an opinion that 'were wrong', and 21.6% answered negatively. Spokesperson Park Jong-hyuk of the KMA said that the survey was conducted to confirm the members' thoughts in response to the government's response to the COVID-19 incident, based on the results of the survey, it is used as a reference for preparing practical measures. Meanwhile, 1589 medical doctors nationwide participated in the survey, with Seoul accounting for the most with 33.9% (538 people), followed by Gyeonggi 17.4% (277 people), Daegu 8.3% (131 people), and Busan 8.2% (130 people).
- Product
- Korea’s first epidemiological report on COVID-19 deaths
- by Lee, in-bok Mar 31, 2020 06:29am
- A study analyzed deaths from COVID-19 in Korea and found male patients in 70s with chronic cardiac disorder like hypertension were critically affected. Apparently, most of them had died in average 10 days after the onset COVID-19 symptoms, and their average time to death was unaffected regardless of underlying illness. First epidemiological report by Korean Society of Infectious Diseases on death due to COVID-19 in Korea Korean Society of Infectious Diseases (KSID) has investigated 53 deaths, as of Mar. 15, from 7,513 patients infected by coronavirus in Korea and published the outcome on the Journal of Korean Medical Science on Mar. 30 (doi.org/10.3346/jkms.2020.35.e132). #Accessing data through Korean Centers for Disease Control and Prevention (KCDC), the researchers conducted a ten-day-long epidemiological investigation on 54 death caused by COVID-19. The investigation found, as of Mar. 15, total 5,833 cases resulted in death among 156,400 confirmed cases of COVID-19 around the world, which recorded 3.7 percent mortality rate. In Korea, the rate was at 0.7 percent with 54 deaths. On Feb. 19, the 104th confirmed case of COVID-19 in Korea has been deceased and was reported as the first COVID-19 caused death in Korea on the next day. And the 443rd case was the first death reported to have been confirmed positive posthumously on Feb. 21. Other than the two, the investigators highlighted the 1,443rd case reported on Feb. 27, as the patient was the first death reported during their self-isolation period. On Mar. 3, the 32nd case has reportedly been deceased without an underlying illness. The investigators also emphasized the descending trend of mortality rate while the number of confirmed cases has exponentially surged since the first death reported. They pointed out it indicates the management over patient with high severity is taking its place. In fact, on Feb. 20 when the first death was reported, the case fatality rate (CFR) was at 1.22 percent. But the CFR was dropped to 0.04 percent, as of Mar. 10. #And as of 12 a.m. Mar. 30, the COVID-19 CFR in Korea was at 0.7 percent. Categorized by each region, the number of deaths was highest in Daegu and Northern Gyeongsang Province, where 85 percent of confirmed cases were concentrated in. Daegu along had 38 patients died from COVID-19, but 13 have lost their lives in Northern Gyeongsang Province. However, the researchers pointed out the statistic figures are not an absolute indicator as a patient from Gangwon Province has died in a Northern Gyeongsang Province hospital, and patients from the Northern Gyeongsang Province have been treated at National Medical Center. Male patients in 70s with underlying health condition, three key words in COVID-19 death So who is most vulnerable to COVID-19? First, the investigators set down three key words—70s, male and underlying cardiovascular disorder. Analyzing critical cases resulted in deaths, the investigation found the median age at death was 75.5. And the mortality rate was higher in male patients at 61.1 percent than in female patients. The most prevalent underlying health condition was cardiovascular disease. The CFR analysis in the report supports the findings clearly. The CFR in male patients was at 1.16 percent with 33 deaths among 2,852 cases, but the rate was at 0.45 percent in female patients with only 21 deaths within 4,661 cases. The gap between sexes was even more significant in the older age group. The mortality rate in male patients 60 and over was at 4.73 percent with eight deaths in 592 cases, where as the rate in female patients in the same age group was at 1.88 percent with 19 deaths in 1,013 cases. # The report claimed the virus-induced death was also closely related to the age group. The CFR in age group of under 20 and 20s to 50s were at zero percent and 0.05 percent, respectively. But from the age group of 50 and up, the CFR was increased to 1.72 percent. Most of the deaths were reported with underlying health condition. Within 90.7 percent of deaths with underlying illnesses, 59.3 percent of them had cardiac disorder like hypertension, making it the most prevalent underlying disorder followed by diabetes and neurologic disease like dementia. The median time from onset symptoms to death of the particular patient group was ten days, regardless of their sex. And also the underlying illness has not affected the duration of survival time. The investigators explained, “Mortality rate is the most crucial indicator to consider when setting the prioritization of infectious disease control. Although it is too early to compare the tendencies with different countries, mortality rate ascending after identifying a mass infection was a meaningful finding.” “The most vital strategy is to maintain the capability of hospitals treating patients in initial stage to severe state by carefully and appropriately reviewing the disease,” and “As these key words from the investigation are the most significant key words as the mortality rate around the world is surging, an improved response with broader perspective based on them is needed.,” the investigators added.
- Product
- Who will succeed in COVID-19 treatment?
- by choi-sun Mar 25, 2020 06:01am
- As pharmaceutical companies around the world are plunging into the development of vaccines and treatments for COVID-19 treatment, attention is focused on who will succeed in commercialization. Among the treatments, Gilead Sciences entered Phase III of clinical trials, and in the field of vaccines, it entered Phase I by Moderna Therapeutics. However, it is not the first to release it because it may fail clinically. Among the other candidates that follow, the mechanism is slightly different, and it is also a concern that they may be able to get the title of a COVID-19 treatment or COVID-19 vaccine. ▲Treatment = Pre-Clinical ~ Phase III There are two ways to respond to the COVID-19. There is a 'therapeutic agent' that suppresses the proliferation of the virus after infection, and there is a 'vaccine' that focuses on preventing infection. COVID-19 is a type of RNA virus that shares its roots with SARS and MERS. A similar principle is that previously used Ebola treatments are used to treat COVID-19. #Remdesivir, an Ebola treatment that Gilead Science is developing, has a mechanism to inhibit RNA polymerase necessary for virus replication and proliferation. It is for this reason that it quickly entered phase III clinical trials. On the 26th of last month, Gilead started phase III of Remdesivir in the United States and China, followed by investigational new drug application on the 2nd of this month in Korea and completed clinical preparation. In fact, Seoul National University Hospital on the 9th concluded a clinical research agreement with the National Institutes of Health and started enrolling patients immediately from this day, so it is expected that the results will be confirmed in the first half of this year. The main goal is whether to lower the boby temperature and get cured within two weeks at the same time. However, it is still unknown whether Ebola virus clinical trials will lead to commercialized products in that it failed with a high mortality rate compared to competing drugs. The rest of the treatment remains in the Pre-Clinical, except that Remdesivir is in Phase III clinical trials. This means that it takes at least one or two years to confirm the reality. Johnson & Johnson is approaching COVID-19 as a treatment and vaccine development based on its past experience in developing Ebola and Zika viruses. Johnson & Johnson is developing a virus-inactivating vaccine at the preclinical stage, and is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop therapeutics for patients who are already infected. Through this, it is examined whether existing medicines, such as Remdesivir, an Ebola treatment, Kaletra, an AIDS treatment, and Avigan, a flu drug developed in Japan, are effective in suppressing COVID-19. US bio-company Regeneron Pharmaceuticals is focusing on the development of antibody therapeutics through genetic engineering. Although it is still in the preclinical stage, Regeneron plans to develop an antibody therapy against COVID-19 through mouse genetic manipulation technology capable of producing human antibodies. The candidate is expected to go into animal testing soon, and is preparing for human clinical trials by the third quarter of this year. In fact, during the Ebola incident in 2015, Regeneron had experience in developing a mixed-antibody drug that doubled the patient's survival rate. Vir Biotechnology is also developing antibody-based therapeutics. The difference from Regeneron is that instead of generating antibodies by genetic manipulation, antibodies that are naturally produced after infection with similar corona-like viruses such as SARS in the past are used. In fact, this method has been applied to MERS and SARS in the past. A method of collecting serum from a patient who formed a natural antibody and administering it to a serious patient was achieved. Vir Biotechnology is investigating whether the SARS virus is similar to COVID-19, so that antibodies from patients recovering from SARS can be isolated and applied to COVID-19. #Vir is in the early stages of development in cooperation with Chinese company WuXi Biologics, and it is not clear when the clinical trial is expected. ▲Vaccine = Pre-Clinical ~ Phase I Currently, phase I is at the forefront from vaccine development. Modena therafutics developed the vaccine candidate mRNA-1273 only 42 days after the nucleotide sequence of the COVID-19 was confirmed and jumped to the promising group. mRNA has a mechanism in the body that allows cells to form antibodies on their own. Modena is expected to begin research next month with healthy volunteers in cooperation with the National Institutes of Health (NIH). Once the safety of mRNA-1273 has been demonstrated, Phase II will be undertaken to confirm the effectiveness of the vaccine in hundreds. However, Modena, which is developing mRNA or mRNA designed for cells in the body to produce antibodies against viruses, has not been approved by the FDA as a related drug. Except for Modena, vaccines of various mechanisms are still in the Pre-Clinical. CureVac, like Modena, develops a vaccine that promotes the production of antibody proteins using synthetic mRNA. It is expected to be ready for clinical trials within a few months. China's Clover Biopharmaceuticals, was transferred its technology to a proprietary adjuvant compound that improves the effectiveness of the vaccine from GSK in February and started developing vaccines. The company is developing a vaccine against infection by injecting a protein that stimulates the immune response and activating body immunity, but the clinical trial plan has not yet been detailed. Inovio, the United States, has been developing DNA medicines for the past 40 years, and has received subsidies for the development of DNA-based vaccines from the Coalition for Epidemic Preparedness Innovations (CEPI). In partnership with Chinese manufacturer Beijing Advaccine Biotechnology, INO-4800 candidate vaccine is in Pre-Clinical, and clinical trials are expected in the second half of this year. Sanofi, which has successfully developed a yellow fever and diphtheria vaccine, is working with the BARDA to develop COVID-19 vaccine. Sanofi aims to create a chimeric DNA vaccine that activates the patient's immunity by mixing a portion of the DNA of COVID-19 with the genetic material of the harmless virus. The vaccine candidate is expected to be tested in the laboratory within 6 months, and the clinical trial is expected to be available within 1 to 18 months. Sanofi said the technology has been applied to SARS. However, Sanofi expects to take at least three years to get approval. Experts say it is too early to make a positive outlook, as various therapeutics and vaccines are still in the Pre-Clinical of exploring candidates and evaluating safety. Professor Ki-seok Jeong of the department of Pulmonology at Hallym University said, "I think it is difficult to cure the drug in the near future. However, in the case of Remdesivir, an ebola drug, it would be better if indications were added as much as it promotes clinical trials in Korea". "An RNA virus has many mutations, so it is not easy to develop a therapeutic drug and it is more difficult to develop a vaccine. Considering that multinational companies spend ￦1 trillion on new drug development, a government-level investment in development is necessary" he advised.
- Product
- Panic buying Tylenol-Advil in fear of COVID-19 fake news
- by Jung, Heung-Jun Mar 04, 2020 06:27am
- Related drugs are experiencing shortage in online pharmacy shops Tylenol and Advil are out of stock as their demands have skyrocketed due to online fake news encouraging panic buying of OTC drugs and claiming the Korean government’s containment of COVID-19 has failed. On Mar. 2, a multiple online pharmacies have posted notice on shortage of Tylenol, Advil and Aspirin. Apparently, the circulating ‘story’ is supposedly a chat between graduates of Seoul National University College of Medicine, which claims the outbreak has entered the ‘community infection’ phase that cannot be contained even with utmost care, and the prognosis of individual would heavily depend on their immune system. The made-up story also talked about concerning stories of how visiting hospital has gotten impossible once infected, and contracting the virus at selected testing sites. The story advised to hoard non-steroidal anti-inflammatory drug, antibiotics and antitussive, expectorant and mucoactive agents, such as aspirin, Advil and Tylenol. It also stressed about acquiring emergency food supply as self-quarantined patients would have to stay at home for over two weeks. The participants in the fake chat also argued seniors and individuals with cardiovascular or respiratory conditions are considered high-risk group. The people in the story assumed and hyped the fear of the public institutes and transportations shutting down. A pharmacist from Songpa-gu, Seoul, wondered “There has been a surge of customers buying specifically Tylenol and aspirins. It seems like inaccurate information has been circulating on Youtube and blogs.” Some pharmacies started securing stocks of the said products with abruptly heightened demands, and pharmacists are conflicted among themselves. Another pharmacist in Gyeonggi province commented, “Some pharmacists were worried about stocking up the drugs in the group chat. Basically they are encouraging panic buying, but as others reprimanded them the group chat was split.” The pharmacist emphasized, “It seems like fake news is kept on regenerated and disseminated. Professional pharmacists should not align themselves with it.” Another pharmacist in Gyeonggi province complained of the fake news spreading through social media as many of senior patients suddenly started looking for aspirin. Pharmacists from other regions have agreed on the problem of spreading inaccurate information as many of their customers were asking for aspirin, Tylenol and antitussive, expectorant and mucoactive agents. A few of pharmacy chains have sent out text messages to member pharmacies to inform purchase limit of Tylenol, and suggested purchasing other options with the same agent.
- Product
- What drug will be replaced by Belviq’s withdrawal?
- by Lee, in-bok Feb 18, 2020 10:49am
- As Ildong’s Belviq, which dominated the obese drug market for a long time, is finally exiting the market, there is a growing interest in which drug will fill this gap. Obesity experts are predicting that safety-oriented prescriptions may be available for the time being, while Saxenda and Qsymia are expected to benefit directly. The Ministry of Food and Drug Safety recently decided to stop selling and recall Belviq(lorcacerin) because of the risk of cancer. The U.S. Food and Drug Administration (FDA) has recommended its recovery, saying the risk is greater than the benefit. As a result, Eisai in charge of the U.S. sales, immediately took over its own collection, and Ildong, a domestic sales company, is also in the process of collecting it. According to IQVIA, a global market research firm, Belviq has been overwhelmingly occupying the No.1 ranking in the obese market until 2018 since it landed in Korea in 2015. Indeed, in 2018, Belviq's outpatient prescriptions amounted to ₩9.07 billion, the highest in the obese drug market, beating Dietamin(₩8.48 billion) and Hutermin (₩7.86 billion). Literally the market dominated by the number one leader suddenly withdrawn from the market is bound to be a big ripple Obesity experts point out that safety will be an issue for obesity prescriptions for the time being. It is believed that Belviq could also create the same situation, reflecting on the safety controversy that has been taking place for the time being after the 2010 Reductil(Sibutramine) eviction Professor A, a member of the Korean society for the study of obesity, said, "The safety issue for obesity drugs persisted for a while even when Reductil was evicted as a cardiovascular safety issue, and Belvik is also likely to create such a situation". What kind of drugs are obese experts considering as a substitute for Belviq? First of all, Saxenda(Liraglutide) is expected to be nearing peak item. Prescriptions have already increased since last year, conquering the obese drug market, and safety issues cannot be ignored. Professor A said, "I think that the Saxenda, which was developed with GLP-1 diabetes, will benefit as much as it has been tested for safety, also, it's already been imprinted on obese patients and for now it's almost the only drug that is free from safety issues". In fact, Saxenda has already led the reorganization of the overweight drug market, surpassing Dietamin(₩9.3 billion) and Belviq(₩8.8 billion), recording outpatient prescription amounts of ₩15.1 billion in the third quarter of 2019. With the disappearance of the biggest competitor among them, there is a prospect that Saxenda’s prescription may be accelerated. However, some are expecting the limited competitiveness of the Saxenda. Rather, Oral medications will be more popular because the characteristics of the drugs are completely different An executive of the DAOR said, “Saxenda has long-term safety data, but it just quotes past clinical trials. Furthermore, there may be a difference in compliance when switching to injection in that Belviq is oral”. He said, "While Qsymia is likely to benefit from the new drug effect, some people are considering Phentamines, which have been prescribed for a long time". Some experts predict that Belviq's withdrawal will not have a big impact on the market right away. Obesity drugs are not a long-term use treatment itself, and it is not urgent enough to change the prescription to another drug right now. Professor B, a member of the Korean society for the study of obesity, said, "Stopping a medication used to treat obesity right away does not cause a problem immediately. Belviq's withdrawal will not have a big impact on the market". In addition, the professor said, "Because it is a drug that has been prescribed a lot, Pharmaceuticals will go for the potion and aggressively market it, but I think that the potion won't be moved to other drugs right now, although the potion may come down".
- Product
- Ebola drug Remdesivir is used to treat COVID-19
- by Lee, In-Bok Feb 13, 2020 06:28am
- Remdesivir by Gilead, which is being developed as an Ebola treatment, is expected to benefit significantly from the spread of COVID-19. The explosive demand for therapeutics around the world has led to unintended recruitment of clinical trials, which has resulted in significant time and cost savings. In some cases, the possibility of quick permits is also increasing. Clinical trials in the US, China, etc, Skip Prior Authorization The National Institute of Allergy and Infectious Diseases (NIAID) announced on the 12th that it will begin a clinical trial of Remdesivir with COVID-19. Remdesivir is a drug that Gilead Science is developing for the Ebola virus, and it is preparing for phase III full-scale after completing phase II clinical trials, However, the analysis predominates that the recruitment of the Ebola virus patient population will be limited and it will take some time due to the budget and time constraints for multinational clinical trials. It is a fact that some aspects of the permit has been placed in a somewhat opaque situation. However, with the rapid rise of Remdesivir in the treatment of new COVID-19, the demand has risen sharply and the environment is ready for immediate clinical trials without prior review and approval. This has been decisive in the case of the first COVID-19 patient from the United States. Indeed, researchers in the Centers for Disease Control and Prevention (CDC) have received a lot of attention from the New England Journal of Medicine (NEJM), with a case report describing the first patient prescribed Remdesivir. At the time, the patient was given other antiviral agents and antibiotics, but the symptoms got worse. Eventually, the administration of Remdesivir improved significantly. Since the Ebola virus is an RNA virus such as COVID-19, Remdesivir, which has a mechanism that prevents RNA replication, also inhibits COVID-19. NEJM Case Report Critical Leads to a quick permit As these effects become known, patients in China and Thailand are already taking Remdesivir in patients. The Chinese government has also urged Gilead to cooperate urgently and to expand the supply of Remdesivir. The same is true for large-scale clinical trials in China ahead of the United States. As soon as the potential for treatment was recognized, the Chinese health authorities immediately approved the medication in the form of clinical trials without prior review or approval. As a result, China has already entered into a controlled trial of 761 patients and is planning to proceed with the trial until April, and then review the rapid approval. This is not the only case in China. The U.S. Food and Drug Administration (FDA) and the CDC also mention rapid approval. Since the drug is already in the form of phase III clinical trials, it is in a position to grant a new drug based on this result. This fact has already been communicated to foreign countries through the New York Times and international press, and for this reason, China and Thailand are reportedly preparing for clinical trials and rapid approval. At the end of last year, the drug, which had even entered phase III clinical trials, was opaque, and in a few months, the phase III clinical trial could be approved for rapid approval. For Gilead, this is a great opportunity to save a great deal of time and budget in collecting patients, selecting institutions, and systematically analyzing them to prepare for permits. However, it is confirmed that clinical trials and rapid approvals are not being reviewed in Korea yet. As China's demand is so large that it attracts the world's quantity, it is not easy to consider prescription even in Korea. "Remdesivir is expected to be effective, but it is not easy to even prescribe it due to the lack of stock in our country, and for this reason, the policy recommendation was to exclude from primary treatment", said Jihwan Bang, the team leader of the central clinical task force (TF). An official from the Ministry of Food and Drug Safety said, "No immediate approval has been reviewed regarding COVID-19 treatment".
